argenex (ARGX) Stock Forecast & Price Target

$652.43 +5.83 (+0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$652.90 +0.47 (+0.07%)

As of 04:35 PM Eastern

argenex - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 20 Analyst Ratings

Sell
0

Hold
0

Buy
20

Based on 20 Wall Street analysts who have issued ratings for argenex in the last 12 months, the stock has a consensus rating of "Buy." Out of the 20 analysts, 18 have given a buy rating, and 2 have given a strong buy rating for ARGX.

Consensus Price Target

$746.81
14.47% Upside

According to the 20 analysts' twelve-month price targets for argenex, the average price target is $746.81. The highest price target for ARGX is $1,070.00, while the lowest price target for ARGX is $605.00. The average price target represents a forecasted upside of 14.47% from the current price of $652.43.

Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenex and its competitors.

ARGX Analyst Ratings Over Time

Type	Current Forecast 8/14/24 to 8/14/25	1 Month Ago 7/15/24 to 7/15/25	3 Months Ago 5/16/24 to 5/16/25	1 Year Ago 8/15/23 to 8/14/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	18 Buy rating(s)	19 Buy rating(s)	20 Buy rating(s)	18 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$746.81	$728.06	$698.11	$540.37
Forecasted Upside	14.47% Upside	30.96% Upside	23.42% Upside	3.45% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

argenex Stock vs. The Competition

Type	argenex	Medical Companies	S&P 500
Consensus Rating Score	3.10	2.81	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	14.47% Upside	12,247.04% Upside	11.48% Upside
News Sentiment Rating	Positive News See Recent ARGX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/4/2025	JPMorgan Chase & Co. 3 of 5 stars	James Gordon Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$775.00 ➝ $830.00	+22.16%
8/1/2025	Morgan Stanley 3 of 5 stars	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$700.00 ➝ $766.00	+14.71%
8/1/2025	Guggenheim 2 of 5 stars	Yatin Suneja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$1,060.00 ➝ $1,070.00	+60.24%
8/1/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$720.00 ➝ $774.00	+15.47%
7/31/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Derek Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$741.00 ➝ $756.00	+12.78%
7/21/2025	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$715.00	+26.29%
7/8/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
5/21/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
5/14/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$699.00	+30.93%
5/13/2025	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
Get the Latest News and Ratings for ARGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for argenex and its competitors with MarketBeat's FREE daily newsletter.
5/13/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joel Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$680.00 ➝ $680.00	+21.23%
5/9/2025	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Leland Gershell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$704.00 ➝ $708.00	+27.59%
3/17/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
2/28/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
1/14/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joon Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$660.00 ➝ $700.00	+3.93%
1/7/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$620.00 ➝ $725.00	+12.34%
11/21/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$675.00 ➝ $706.00	+19.29%
11/12/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$697.00	+18.35%
11/5/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$439.00 ➝ $715.00	+21.46%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy	$605.00	+16.23%
8/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Pitman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
6/24/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$535.00 ➝ $607.00	+40.57%
6/24/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$485.00 ➝ $500.00	+14.82%
12/12/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$612.00 ➝ $641.00	+41.35%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$605.00 ➝ $628.00	+29.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:42 PM ET.

Should I Buy argenex Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 12, 2025. Please send any questions or comments about these argenex pros and cons to contact@marketbeat.com.

argenex
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

The company recently reported an impressive earnings per share (EPS) of $3.74, significantly exceeding analyst expectations, which indicates strong financial performance and potential for future growth.
With a return on equity of over 21%, argenx SE demonstrates effective management and profitability, suggesting that the company is generating good returns on shareholders' investments.
The current stock price is around $720, reflecting a positive market sentiment and potential for appreciation as the company continues to develop its innovative therapies.
Analysts have a consensus rating of "Buy" for argenx SE, with many recent upgrades to "strong-buy" from reputable firms, indicating confidence in the company's future prospects.
Argentx SE is actively developing therapies for various autoimmune diseases, which positions the company well in a growing market with significant unmet medical needs.

argenex
Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

Despite strong recent performance, the biotechnology sector can be highly volatile, and argenx SE may face challenges related to regulatory approvals for its therapies.
The company has a high net margin of nearly 41%, which, while impressive, may not be sustainable in the long term as competition increases in the biotechnology field.
Market conditions can change rapidly, and any downturn could negatively impact the stock price, even if the company's fundamentals remain strong.
Investors should consider the risks associated with the development of new therapies, as clinical trials can fail, leading to significant financial losses.
While the company has a strong product pipeline, the success of these products is uncertain, and any delays or failures could adversely affect investor confidence.

ARGX Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for argenex is $746.81, with a high forecast of $1,070.00 and a low forecast of $605.00.
: 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenex in the last twelve months. There are currently 18 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARGX shares.
: According to analysts, argenex's stock has a predicted upside of 14.47% based on their 12-month stock forecasts.
: Over the previous 90 days, argenex's stock had 1 upgrade by analysts.
: argenex has been rated by research analysts at Citigroup, Deutsche Bank Aktiengesellschaft, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Wedbush, and Wells Fargo & Company in the past 90 days.
: Analysts like argenex more than other "medical" companies. The consensus rating for argenex is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ARGX) was last updated on 8/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Stock Forecast & Price Target